Navigation Links
Risk of leukemia after cancer chemotherapy persists
Date:2/14/2013

(WASHINGTON)- While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

Chemotherapy is often a highly effective treatment for cancer, but certain drugs have also been shown in a range of studies to increase a patient's risk of developing therapy-related acute myeloid leukemia (tAML), a rare but frequently fatal condition. Thanks to significant advancements in therapy resulting in improved patient survival rates for certain cancers over the last several decades, researchers and clinicians now aim to design treatment regimens that maximize patient survival while minimizing short- and long-term complications.

"In the course of improving interventions and survival rates in many types of cancer, we have learned that certain chemotherapies can cause damage to cells in the bone marrow, increasing a patient's risk of leukemia. However, no recent large-scale studies have evaluated how the risk of treatment-related leukemia has evolved with the changing treatment strategies," said Lindsay Morton, PhD, of the National Cancer Institute (NCI) and lead author of the study.

To examine how the risk of tAML has evolved over time among cancer patients treated with chemotherapy, Dr. Morton and a team of researchers at the NCI's Division of Cancer Epidemiology and Genetics evaluated data from cancer registries in the U.S. Surveillance, Epidemiology, and End Results (SEER) Program, identifying adult patients ages 20-84 who were diagnosed with cancer (any type) between 1975 and 2008 and who were treated with chemotherapy. SEER data files were reviewed to determine tAML risk based on first type of cancer, time since diagnosis, age at diagnosis, and year of diagnosis.

Among the 426,068 patients whose data were eligible for analysis, Dr. Morton's team confirmed 801cases of tAML, nearly five times more than the number of cases expected in the general population. To help explain the changes in relative risk over time, investigators compared the trends in the data with evolving treatment recommendations and major therapeutic discoveries as described in the medical literature. While patient information in the SEER database did not include data on specific drugs or doses, the incidence trends were consistent with changing treatment practices and the toxicities associated with certain chemotherapies. Notably, the proportion of patients receiving chemotherapy, both with or without radiotherapy, increased during the study period for many malignancies.

As the team compared tAML risks with trends in cancer treatment over time, they analyzed several factors that likely contributed to the differences in risk between patients, including the type of cancer initially diagnosed and the year of diagnosis. For example, trends in risk for breast cancer patients (which comprised roughly one-third of tAML cases in the study) correlated to changes in breast cancer treatment protocols over the last several decades, suggesting that the decrease in tAML risk observed among breast cancer survivors in the 1980s might be attributable to an increased use of cyclophosphamide-based chemotherapy, which is less likely to cause leukemia than earlier treatment options.

A similar decline in risk was observed among ovarian cancer patients, possibly linked to a shift in ovarian cancer chemotherapy treatment in the 1970s from melphalan, a type of chemotherapy that has been shown to trigger leukemia, to a less toxic platinum-based chemotherapy. In contrast, tAML risks increased over the last several decades among patients treated with chemotherapy for non-Hodgkin lymphoma (NHL), possibly as a result of improvements in survival for patients who received multiple courses of treatment.

Further, Dr. Morton's team identified newly elevated tAML risks for patients treated with chemotherapy since 2000 for esophageal, anal, cervical, and prostate cancers, and since the 1990s for bone/joint and endometrial cancers risks that could potentially be related to expanding use of chemotherapy in recent years. Patients diagnosed with myeloma today still face some of the highest risks for tAML, possibly due to the ongoing use of melphalan to fight the aggressive disease.

The database analysis also found that relative tAML risk for many patients tended to decline with increasing time since initial cancer diagnosis. For those with non-hematologic malignancies, there was no evidence of elevated tAML risks more than 10 years following diagnosis, whereas risks persisted more than 10 years after diagnosis for patients with Hodgkin lymphoma (HL), NHL, and myeloma. Heightened tAML risk among these patients could be linked to the higher intensity and longer duration of their treatment.

"Future studies should identify patients at the highest risk of tAML so that the risks can be weighed against the benefits of chemotherapy, particularly for cancers with favorable long-term survival," said Dr. Morton. "Further research is also warranted to assess the risks associated with new targeted and immunomodulatory agents by including secondary malignancies such as tAML as endpoints in prospective clinical studies of new agents or new uses of standard agents."


'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. To prevent leukemias dreaded return, go for the stem cells
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Study Shows New Option for Kids With Tough-to-Treat Leukemia
4. Therapy exploits addiction of leukemia cells
5. Study identifies potential treatment for lethal childhood leukemia
6. A microRNA prognostic marker identified in acute leukemia
7. VCU Massey Cancer Center sees potential in novel leukemia treatment
8. Inherited DNA change explains overactive leukemia gene
9. New drug strategy attacks resistant leukemia and lymphoma
10. Researchers identify a life-and-death molecule on chronic leukemia cells
11. Child CT Scans Might Up Risk of Brain Cancer, Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: